PT Kalbe Farma Tbk stock (ID1000096605): Indonesia healthcare name under pressure after late-May slide

PT Kalbe Farma Tbk shares on the Indonesia Stock Exchange were weaker in late May trading, keeping attention on the Jakarta-listed healthcare group as investors weigh earnings trends and sector dynamics in its home market.

PT Kalbe Farma Tbk shares in Indonesia traded lower in the final days of May, leaving the Jakarta-listed healthcare stock on the defensive as investors reassessed its positioning in the domestic pharmaceutical and consumer health market. The stock, which is listed on the Indonesia Stock Exchange under the ticker KLBF, remains closely watched in its home market as one of the country's better-known healthcare names.

The group, headquartered in Jakarta, is a key constituent of Indonesia's pharmaceutical sector and its share price is typically driven by expectations for prescription drugs, over-the-counter products, nutritionals and distribution businesses in the local market. The moves in late May highlighted how sentiment around earnings momentum, input costs and regulatory developments in Indonesia's healthcare system continue to influence trading in KLBF.

On the Indonesia Stock Exchange, the stock traded in Indonesian rupiah and is part of the broader universe of healthcare and consumer names followed closely by domestic institutional and retail investors. Trading volumes around the end of May indicated that market participants were actively repositioning in the name, reflecting a mix of macro considerations in Indonesia and sector-specific debates about growth and margins.

For investors in Europe following Indonesian stocks, PT Kalbe Farma Tbk can also be accessed via off-exchange trading platforms such as Tradegate in Germany, where it is quoted in euros and provides an additional route to gain exposure to the Jakarta-listed healthcare group. However, liquidity and pricing remain anchored in its home market in Indonesia.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Kalbe Farma
• Sector/industry: Pharmaceuticals, consumer health and nutrition
• Headquarters/country: Jakarta, Indonesia
• Core markets: Indonesia and selected Southeast Asian countries
• Key revenue drivers: Prescription pharmaceuticals, over-the-counter medicines, nutritionals and distribution services
• Home exchange/listing venue: Indonesia Stock Exchange (KLBF)
• Trading currency: IDR

PT Kalbe Farma Tbk: core business model

PT Kalbe Farma Tbk operates as a diversified healthcare group in Indonesia, generating revenue mainly from branded pharmaceuticals, consumer health products, nutritionals and an extensive domestic distribution network.

What banks and research houses say about PT Kalbe Farma Tbk

No verified analyst coverage was identified at the time of publication.

Conclusion

The recent weakness in PT Kalbe Farma Tbk's Jakarta-listed shares keeps the Indonesian healthcare group in focus as investors track trading patterns and sentiment in its home market. With no fresh, verifiable analyst updates available at the time of writing, the market is likely to remain driven by expectations for Indonesia's healthcare spending, regulatory backdrop and the company's ability to grow its core pharmaceuticals and consumer health businesses.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.